| CAS |
440-17-5 |
| Chinese Name |
三氟拉嗪二盐酸盐 |
| English Name |
Trifluoperazine Dihydrochloride |
| Synonyms |
盐酸三氟拉嗪;SKF5019;Urinox |
| Molecular Formula |
C21H26Cl2F3N3S |
| Molecular Weight |
480.42 |
| Solubility |
Soluble in Water/DMSO(Need ultrasonic) |
| Purity |
≥98% |
| Appearance |
White to off-white Solid |
| Storage |
Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC |
EINECS 207-123-0 |
| MDL |
MFCD00012656 |
| SMILES |
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl |
| InChIKey |
BXDAOUXDMHXPDI-UHFFFAOYSA-N |
| InChI |
InChI=1S/C21H24F3N3S.2ClH/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22，23)24;;/h2-3，5-8，15H，4，9-14H2，1H3;2*1H |
| PubChem CID |
66064 |
| Target Point |
Dopamine Receptor;Adrenergic Receptor;NUPR1 ;calmodulin;P-glycoprotein |
| Passage |
Neuronal Signaling;GPCR & G Protein;Endocrinology & Hormones;Membrane Transporter/Ion Channel; |
| Background |
Trifluoperazine is an antipsychotic compound that acts by blocking central dopamine receptors. Trifluoperazine is an effective α 1-adrenergic receptor antagonist and NUPR1 inhibitor have anti-cancer activity. Trifluoperazine is a calmodulin inhibitor that also inhibits P-glycoprotein. |
| Biological Activity |
Trifluoperazine Dihydrochloride 是一种多巴胺D2受体抑制剂，是一种强效的α1-肾上腺素能受体拮抗剂，一种有效的 NUPR1 抑制剂，被用作钙调蛋白抑制剂，还能抑制 P-糖蛋白，被用于治疗精神类疾病，具有抗癌活性。[1-4] |
| In Vitro |
Trifluoperazine inhibited in a dose-dependent manner the stimulation of glycogenolysis，gluconeogenesis，and ureogenesis due to alpha 1-adrenergic stimulation in rat hepatocytes. Trifluoperazine are much more potent at alpha 1- than at alpha 2-adrenergic receptors.[2] In the concentration range of 20-35 microM，TFP acts as a reversible inhibitor of influenza virus morphogenesis，but not budding，by disturbing cellular CaM and/or CaM-dependent functions.[4] |
| In Vivo |
Trifluoperazine(TFP)，an antipsychotic agent，was capable of binding to NUPR1 and inhibiting tumors growth，showed strong central nervous system side-effects.[1] |
| Data Literature Source |
[1]. Santofimia-Casta o P，et al.. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019 Mar 28;129(6):2500-2513.
[2]. Huerta-Bahena J，et al. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70.
[3]. Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016 Jan;54(1):20-2.
[3]. Ochiai H，et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991 Feb;15(2):149-60. |
| Unit |
Bottle |
| Specification |
100mg 250mg |
English
中文
Manual Download
